Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Indicated prevention with long-chain polyunsaturated omega-3 fatty acids in patients with 22q11DS genetically at high risk for psychosis. Protocol of a randomized, double-blind, placebo-controlled treatment trial.
[22q11.2 deletion syndrome]
It
has
been
found
that
long
-chain
omega-
3
polyunsaturated
fatty
acids
(
PUFAs
)
reduce
the
risk
of
progression
to
first
episode
of
psychosis
(
FEP
)
and
may
offer
a
safe
and
efficacious
strategy
for
selective
and
indicated
prevention
in
young
people
with
ultra-
high
-risk
(
UHR
)
states
.
An
opportunity
for
exploring
the
trajectory
of
FEP
and
for
investigating
the
efficacy
of
preventive
treatments
exists
in
22
q
11
.
2
deletion
syndrome
(
22
q
11
DS
)
,
which
has
a
30
%
psychotic
transition
rate
.
The
fact
that
22
q
11
DS
patients
are
more
homogeneous
than
other
UHR
groups
and
are
characterized
by
high
level
of
negative
symptoms
provides
a
strong
rationale
for
the
use
of
PUFAs
.
The
principal
aim
of
the
present
trial
is
to
investigate
the
effects
of
PUFAs
in
individuals
with
22
q
11
DS
who
are
at
UHR
for
developing
FEP
.
A
prospective
,
randomized
,
double
-blind
,
placebo-controlled
,
single
-centre
study
design
will
be
used
.
Eighty
individuals
aged
12
-
26
will
be
randomly
assigned
to
two
treatment
conditions
.
The
experimental
group
will
receive
PUFAs
.
The
placebo
group
will
receive
paraffin
oil
.
Standard
clinical
assessments
and
neuropsychological
tests
will
be
performed
at
baseline
and
at
8
-
,
12
-
,
26
-
and
52
-
week
follow-up
.
Blood
samples
will
be
collected
at
baseline
and
after
12
weeks
.
This
study
is
registered
as
an
International
Standard
RCT
,
number
02070211
.
The
corresponding
author
is
supported
by
a
NARSAD
Young
Investigator
Award
.
T
his
is
the
protocol
of
a
planned
study
that
aims
to
test
the
efficacy
of
PUFAs
in
the
prodromal
phase
of
FEP
,
in
a
specific
syndrome
where
there
is
strong
evidence
that
a
high
genetic
load
is
involved
in
the
disorder
.
Diseases
Validation
Diseases presenting
"high genetic load"
symptom
22q11.2 deletion syndrome
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom